Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Farmers Insurance
Medtronic
Merck
Cantor Fitzgerald
Baxter
Harvard Business School
McKinsey
Covington

Generated: December 10, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PLECANATIDE

« Back to Dashboard

Clinical Trials for Plecanatide

Trial ID Title Status Sponsor Phase Summary
NCT01429987 The Plecanatide Chronic Idiopathic Constipation (CIC) Study Completed Parexel Phase 2/Phase 3 This is a randomized, double-blind, placebo controlled, 12 week repeat oral dose, dose ranging study to determine the efficacy and safety of 3 doses of plecanatide compared to placebo in patients with Chronic Idiopathic Constipation (CIC).
NCT01429987 The Plecanatide Chronic Idiopathic Constipation (CIC) Study Completed Synergy Pharmaceuticals Inc. Phase 2/Phase 3 This is a randomized, double-blind, placebo controlled, 12 week repeat oral dose, dose ranging study to determine the efficacy and safety of 3 doses of plecanatide compared to placebo in patients with Chronic Idiopathic Constipation (CIC).
NCT01722318 The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C) Completed Synergy Pharmaceuticals Inc. Phase 2 This is a randomized, 12-week, double-blind, placebo-controlled, dose-ranging study in patients with IBS-C.
NCT01919697 Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC) Completed INC Research Phase 3 This is a multi-center, open-label, 52-week safety and tolerability study of plecanatide in patients with Chronic Idiopathic Constipation (CIC).
NCT01919697 Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC) Completed Synergy Pharmaceuticals Inc. Phase 3 This is a multi-center, open-label, 52-week safety and tolerability study of plecanatide in patients with Chronic Idiopathic Constipation (CIC).
NCT01982240 12-Week Study of Plecanatide for CIC (The CIC3 Study) Completed Synergy Pharmaceuticals Inc. Phase 3 The purpose of this study is to confirm that the investigational medication, plecanatide, is safe and effective in treating chronic idiopathic constipation.
NCT02122471 12-Week Study of Plecanatide for CIC (The National CIC3 Study) Completed Synergy Pharmaceuticals Inc. Phase 3 The purpose of this study is to confirm that the investigational medication, plecanatide, is safe and effective in treating chronic idiopathic constipation.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Plecanatide

Condition Name

Condition Name for Plecanatide
Intervention Trials
Chronic Idiopathic Constipation 4
Irritable Bowel Syndrome Characterized by Constipation 3
Irritable Bowel Syndrome With Constipation 2
Irritable Bowel Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Plecanatide
Intervention Trials
Constipation 9
Irritable Bowel Syndrome 6
Syndrome 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Plecanatide

Trials by Country

Trials by Country for Plecanatide
Location Trials
United States 283
Canada 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Plecanatide
Location Trials
Texas 9
Florida 9
California 9
Virginia 9
Louisiana 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Plecanatide

Clinical Trial Phase

Clinical Trial Phase for Plecanatide
Clinical Trial Phase Trials
Phase 3 6
Phase 2/Phase 3 1
Phase 2 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Plecanatide
Clinical Trial Phase Trials
Completed 5
Recruiting 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Plecanatide

Sponsor Name

Sponsor Name for Plecanatide
Sponsor Trials
Synergy Pharmaceuticals Inc. 10
INC Research 1
Parexel 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Plecanatide
Sponsor Trials
Industry 11
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
McKinsey
Express Scripts
Healthtrust
AstraZeneca
Cipla
Colorcon
Harvard Business School
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.